Phio Pharmaceuticals Corp. (PHIO) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.86 (-5.91% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PHIO ranks #594 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $10.1M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).
Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $0 in revenue, -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PHIO currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($0.90) forces dealer call-delta covering toward $4.40.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Phio Pharmaceuticals Corp. (PHIO) dropped -5.91% to $0.86, trading at 2% of its 52-week range ($0.81 – $4.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical com
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PHIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PHIO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Phio Pharmaceuticals Corp. (PHIO) ranks #594 by composite RQD confidence (42/100, grade D-) and #896 by equity capitalization ($10.0M). Within this direct 5-issuer industry benchmark cohort, PHIO leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with PHIO at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PHIO
ACTIVE
Phio Pharmaceuticals Corp. | D- | 42/100 | — | — | -35.0% | -5.91% | $10.0M | Benchmark Subject |
| BLRX BioLineRx Ltd. | C- | 60/100 | — | — | — | +1.00% | $10.1M | /blrx-vs-phio → |
| GDTC CytoMed Therapeutics Limited | D+ | 54/100 | — | — | — | -3.68% | $10.7M | /gdtc-vs-phio → |
| TPST Tempest Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -1.24% | $10.7M | /tpst-vs-phio → |
| BFRG Bullfrog AI Holdings Inc. | D- | 40/100 | — | 18.8% | -35.0% | +3.88% | $9.4M | /bfrg-vs-phio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Phio Pharmaceuticals Corp. (PHIO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.7M, operating cash flow of -$8.0M, and free cash flow of -$8.0M (-12.3% YoY). On the balance sheet, PHIO closed FY2025 with $21.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$8.7M | -$8.0M | -$8.0M | $21.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$7.2M | -$7.1M | -$7.1M | $5.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.8M | -$10.7M | -$10.7M | — | — |
As of 2026-11-01, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.86 (-5.91% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PHIO ranks #594 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $10.1M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).
Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $0 in revenue, -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PHIO last traded at $0.86 (-5.91% on volume of 26,721 shares), positioning the stock -14.00% below its 50-day simple moving average ($1.00) and -21.10% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.81 to $4.19, PHIO sits at the 1.5% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.97).
Why PHIO Stock dropped -5.91% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.